The NF Research Initiative at Boston Children’s Hospital opened two grant opportunities for projects that will create a Synodos-like consortium for patient-derived xenograft (PDX) and organoids MPNST that will lead to new models for MPNST and identify new therapeutics.
RFA for an NF1-Related MPNST Patient-Derived Model Development and Testing Centers (MDTCs)
The NF1 Research Initiative (NFRI) mission is to advance pre-clinical research towards effective treatment of neurofibromatosis-related tumors. The initial focus of the NFRI will be on malignant peripheral nerve sheath tumors (MPNSTs), for which there is currently no effective medical treatment.
The purpose of these RFAs, worth $1.5M, is to produce actionable pre-clinical data about response to single agent and combination agents using patient-derived NF1-related MPNST models such as PDX and organoids, with the goal of informing human clinical trials for NF1-related MPNST. These awards will support a project similar to the National Cancer Institute’s PDX_net.
IMPORTANT DATES:
Submit a 1-page letter of intent (LOI) by Thursday, August 22, 2019 at noon EDT
Response to LOI (invitation to submit) within 1 week of receipt of LOI
Full application (if invited) by October 14, 2019 at noon EDT
Award notice: November 27, 2019
Funds available as of January 1, 2020 (pending contract)
For more information, please visit https://www.nfresearch-childrens.org/grants.
